Search
C326
go.drugbank.com/drugs/DB06017ExperimentalThe drug is composed of an IL-6–binding trimer and a IgG-binding domain. … C326 is an investigational compound under investigation in clinical trial NCT00353756 (Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease) for the treatment
Arbaclofen Placarbil
go.drugbank.com/drugs/DB08892InvestigationalArbaclofen Placerbil was believed to have therapeutic potential in treating gastroesophogeal reflux disease (GERD) and plasticity; however due to discouraging clinical trial results, the drug was abandoned … It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties.
Human botulinum neurotoxin A/B immune globulin
go.drugbank.com/drugs/DB14115Approved[L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism.
Trastuzumab emtansine
go.drugbank.com/drugs/DB05773ApprovedInvestigationalThe FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged.
CYT-6091
go.drugbank.com/drugs/DB05991ExperimentalCYT-6091 (Aurimune) is an investigational small molecule made up of recombinant human tumor necrosis factor alpha (rhTNF) and thiolyated polyethylene glycol bound to the surface of 27 nm colloidal gold
PH-284
go.drugbank.com/drugs/DB05452ExperimentalVomeropherins are self-administered by the patient with a metered nasal spray, or nasal aerosol device so that they can bind to peripheral chemosensory receptors in the nasal passages.
Glafenine
go.drugbank.com/drugs/DB08963ApprovedWithdrawnAn anthranilic acid derivative with analgesic properties used for the relief of all types of pain. Glafenine is withdrawn from the American market.
Glyceryl monostearate
go.drugbank.com/drugs/DB11250ApprovedIt is commonly used as an emulsifier in foods.